199 related articles for article (PubMed ID: 8342071)
21. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.
Grochow LB; Jones RJ; Brundrett RB; Braine HG; Chen TL; Saral R; Santos GW; Colvin OM
Cancer Chemother Pharmacol; 1989; 25(1):55-61. PubMed ID: 2591002
[TBL] [Abstract][Full Text] [Related]
22. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
[TBL] [Abstract][Full Text] [Related]
24. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
[TBL] [Abstract][Full Text] [Related]
25. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S; Wiley J
Anticancer Drugs; 2004 Jun; 15(5):453-9. PubMed ID: 15166618
[TBL] [Abstract][Full Text] [Related]
26. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
Bleyzac N
Fundam Clin Pharmacol; 2008 Dec; 22(6):605-8. PubMed ID: 19049662
[TBL] [Abstract][Full Text] [Related]
27. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
28. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
Chattergoon DS; Saunders EF; Klein J; Calderwood S; Doyle J; Freedman MH; Koren G
Bone Marrow Transplant; 1997 Sep; 20(5):347-54. PubMed ID: 9339748
[TBL] [Abstract][Full Text] [Related]
29. The role of busulfan in bone marrow transplantation.
Hassan M
Med Oncol; 1999 Sep; 16(3):166-76. PubMed ID: 10523796
[TBL] [Abstract][Full Text] [Related]
30. New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.
Devine SM; Geller RB; Holland HK; Wingard JR; Saral R
Semin Oncol; 1993 Aug; 20(4 Suppl 4):56-63; quiz 64. PubMed ID: 8342077
[TBL] [Abstract][Full Text] [Related]
31. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.
Vassal G; Koscielny S; Challine D; Valteau-Couanet D; Boland I; Deroussent A; Lemerle J; Gouyette A; Hartmann O
Cancer Chemother Pharmacol; 1996; 37(3):247-53. PubMed ID: 8529285
[TBL] [Abstract][Full Text] [Related]
32. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia.
Pawlowska AB; Blazar BR; Angelucci E; Baronciani D; Shu XO; Bostrom B
Bone Marrow Transplant; 1997 Dec; 20(11):915-20. PubMed ID: 9422469
[TBL] [Abstract][Full Text] [Related]
33. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
34. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
[TBL] [Abstract][Full Text] [Related]
36. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
37. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
[TBL] [Abstract][Full Text] [Related]
38. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
[TBL] [Abstract][Full Text] [Related]
40. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
